cancer

Andrew Ruane underwent the procedure in the early days of the UCLA Health adult bone marrow transplant program.

Health economist Susan Ettner, physician-scientist Donald Kohn and cancer researcher Dennis Slamon are among the 100 new members of the academy’s class of 2026.

A UCLA study of more than 14,000 patient-drug pairs finds insurers and patients paid less for biosimilars than for brand-name biologics.

Even as she was coming to terms with the diagnosis, Ava Hernandez was dreaming of playing again.

While learning about brain tumors in medical school, Dr. Paul Lukac discovered he had one.

A gene expression test identifies the first three years after childbirth as a potential window of higher biological risk.

A UCLA-led study finds changing the terminology for Grade Group 1 prostate cancer may reduce overtreatment while encouraging more appropriate screening.

UCLA's Steven Jonas uses nanotechnology in his lab to explore cancer and other disease-fighting tools.

UCLA study finds creatine supplementation significantly slowed tumor growth in mice.

Targeted therapy with the drug daraxonrasib significantly improves survival and tumor response compared with chemotherapy.

At UCLA, Dr. David Nathanson is designing new therapies that tackle glioblastoma’s unique tumor biology, aiming to overcome long-standing treatment challenges.

The test could offer a more affordable approach to early disease detection.

The advance could lead to safer, more effective T cell therapies for prostate cancer and other solid tumors.

CAR-NKT cell therapy can be produced at a fraction of the cost of personalized treatments.

By equipping T cells with two proteins derived from fungi, the researchers enabled the immune cells to import cellobiose and convert it into usable glucose inside the cell.

The UCLA Research Park is two years away from opening its doors. But it’s already buzzing with energy and ideas.

The research team engineered human blood stem cells to produce specialized immune cells called NKT cells.

The gift will support the UCLA-Caltech Medical Scientist Training Program by funding an endowed chair and a fellowship.

The study is the first large-scale clinical trial to show that a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer.

Simms/Mann dietitian Deborah Hong discusses the link between excessive sugar and cancer risk.

Bruingenuity is on vivid display in myriad inventions that save and improve lives every day. Bonus: gourmet slime!

As a child, Tae-León Butler received lifesaving cancer treatment at UCLA. Now, she’s back on campus to become a pediatric oncology physician herself.

With 285 new inventions last year alone, UCLA’s research and creative activities are powering progress far beyond campus.

Listen to Knaul, associate of the UCLA chancellor and a distinguished professor of medicine, on UCLA Health’s “Medically Speaking” podcast.

Following the team’s discovery, researchers have identified a strategy to possibly prevent treatment relapses.